Living With T1D/August 25, 2026/2 min read

What Adults With Type 1 Diabetes Really Want From Closed-Loop Systems

A new study of 166 adults using closed-loop therapy reveals what matters most to them—and how their priorities shift with age. Here's what they say is working.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

Sensor accuracy, blood sugar performance, and tube-free pump options top the list of what adults prioritize when choosing closed-loop equipment
Younger adults care most about reducing daily burden and improving quality of life, while older adults prioritize preventing low blood sugars
Most adults report that closed-loop therapy improves their quality of life, reduces both highs and lows, and meets their expectations
Many adults see value in tight blood sugar ranges but fewer believe those targets are actually achievable for them

What Matters When Choosing Closed-Loop Equipment

When adults with Type 1 diabetes consider switching to closed-loop systems, they think about different things. A recent study of 166 adults found that the most important factor when choosing a continuous glucose monitor (CGM) is sensor accuracy—cited by 39.3% of participants. Reliable readings matter because they form the foundation of how the system works.

For the algorithm—the brain of the closed-loop system—glycaemic performance came out on top at 37.6%. Adults want to know the system will actually manage their blood sugar effectively. When it comes to the insulin pump itself, 27.5% prioritized pumps without tubing, valuing the convenience and discretion of a patch pump.

Age Changes What Matters Most

The study revealed an important shift based on age. Younger adults more often prioritized reducing the overall burden of managing Type 1 diabetes and improving their quality of life. Older adults, by contrast, were more focused on preventing and treating hypoglycemia—low blood sugar episodes.

This difference suggests that closed-loop systems may need to address different goals depending on who is using them. For some, the goal is freedom from constant management. For others, safety from dangerous lows is the priority.

Do Closed-Loop Systems Deliver?

Most adults in the study reported positive experiences. About 78.6% said closed-loop therapy improved their quality of life. Three-quarters (75.0%) reported that it reduced high blood sugars, and 72.3% said it reduced low blood sugars. Overall, 81.1% said the therapy met their expectations.

These results suggest that for most adults already using closed-loop systems, the technology is doing what they hoped it would do.

The Gap Between What's Beneficial and What Feels Possible

The study also looked at how adults view tight blood sugar ranges—specifically, keeping glucose between 3.9 and 7.8 mmol/L (roughly 70–140 mg/dL) for at least 50% of the time. A majority of participants (63.8%) recognized this as beneficial for their health.

However, only 36.1% actually believed this target was achievable for them personally. This disconnect points to an important challenge: even when people understand the value of a goal, they may not feel it's realistic given their individual circumstances, daily life, or how their body responds to insulin.

Evidence label

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.